Evidence map›Paper›PMID 35433607›Full record

ArticleFrontiers in public health2022

Tweet Analysis for Enhancement of COVID-19 Epidemic Simulation: A Case Study in Japan.

Vu Tran, Tomoko Matsui

Abstract read
In one paragraph

Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. COVID-19 case prediction using emotion trendsFrontiers in public health · 2023
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Vu TranRisk Analysis Research Center, The Institute of Statistical Mathematics, Tokyo, Japan.
Tomoko MatsuiRisk Analysis Research Center, The Institute of Statistical Mathematics, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic, which began in December 2019, progressed in a complicated manner and thus caused problems worldwide. Seeking clues to the reasons for the complicated progression is necessary but challenging in the fight against the pandemic. We sought clues by investigating the relationship between reactions on social media and the COVID-19 epidemic in Japan. Twitter was selected as the social media platform for study because it has a large user base in Japan and because it quickly propagates short topic-focused messages ("tweets"). Analysis using Japanese Twitter data suggested that reactions on social media and the progression of the COVID-19 epidemic may have a close relationship. Analysis of the data for the past waves of COVID-19 in Japan revealed that the relevant reactions on Twitter and COVID-19 progression are related repetitive phenomena. We propose using observations of the reaction trend represented by tweet counts and the trend of COVID-19 epidemic progression in Japan and a deep neural network model to capture the relationship between social reactions and COVID-19 progression and to predict the future trend of COVID-19 progression. This trend prediction would then be used to set up a susceptible-exposed-infected-recovered model for simulating potential future COVID-19 cases. Experiments to evaluate the potential of using tweets to support the prediction of how an epidemic will progress demonstrated the value of using epidemic-related social media data. Our findings provide insights into the relationship between user reactions on social media, particularly Twitter, and epidemic progression, which can be used to fight pandemics.

Indexed as

COVID-19Social MediaHumansJapanPandemicsSARS-CoV-2COVID-19emojiemotionSEIR modelsimulationSNSTwitter

Identifiers

PMID35433607
PMCPMC9008370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.